Friday, March 24, 2023
HomeIndiaDrug authority clears use of India’s first nasal Covid-19 vaccine made by...

Drug authority clears use of India’s first nasal Covid-19 vaccine made by Bharat Biotech

The Covaxin maker’s nasal shot will be used in emergency situations for the 18+ age group, Union Health Minister Mansukh Mandaviya tweeted.

Text Size:

New Delhi: The government on Tuesday cleared for use Bharat Biotech’s nasal vaccine – the country’s first – to boost its continuing fight against Covid-19. The vaccine will be used by adults in emergency cases.

Union Health Minister Mansukh Mandaviya tweeted: “Bharat Biotech’s ChAd36-SARS-CoV-S Covid-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved… for primary immunization against Covid-19 in 18+ age group for restricted use in emergency situation”.

“This step will further strengthen our collective fight against the pandemic,” the minister said.

On Independence Day, Bharat Biotech International Limited (BBIL) announced that its COVID-19 intranasal vaccine (BBV154) had proven to be “safe, well-tolerated, and immunogenic” in subjects in controlled phase III clinical trials.

BBV154, which has been specifically formulated to allow intranasal delivery, is designed and developed to be cost-effective in low and middle-income countries, the company said.

Bharat Biotech created the vaccine in partnership with Washington University St Louis, which had developed the recombinant adenoviral vectored constructs and evaluated them in preclinical studies for efficacy.

The Indian vaccine-maker, on its part, conducted the product development related to pre-clinical safety evaluation, the large-scale manufacturing scale-up, the formulation, the delivery-device development, and human clinical trials.

The Centre partially funded the product development and clinical trials through the Department of Biotechnology’s, COVID Suraksha programme.

Bharat Biotech has also said the intranasal vaccine will make it easier to deploy in mass immunisation campaigns with an easy-to-administer formulation and delivery device.

Also read: Sonia Gandhi tests positive for Covid, second time in two months


Subscribe to our channels on YouTube & Telegram

Support Our Journalism

India needs fair, non-hyphenated and questioning journalism, packed with on-ground reporting. ThePrint – with exceptional reporters, columnists and editors – is doing just that.

Sustaining this needs support from wonderful readers like you.

Whether you live in India or overseas, you can take a paid subscription by clicking here.

Support Our Journalism

Most Popular